Journal Article

The ‘target tissues’ as orchestrators of autoimmune responses: the paradigm of Sjögren’s syndrome

Clinical and Experimental Immunology, Volume 220, Issue 1, 2026, uxaf078, https://doi.org/10.1093/cei/uxaf078
Published:
16 December 2025
Article history
Received:
08 July 2025
Revision received:
21 October 2025
Accepted:
12 November 2025
Published:
16 December 2025

Abstract

Systemic autoimmune diseases have been traditionally studied with a special focus on the immune system and less attention was paid to the roles of target tissues that are being exposed to the immune assault. For many common autoimmune diseases accumulating data unravel and highlight the potential role of the target tissues as orchestrators of the autoimmune responses. In this selective review, using Sjögren’s disease (SjD) as a paradigm, we discuss the role of salivary gland epithelial cells (SGEC) not as innocent bystander targets of autoimmune responses, but rather as initiators and amplifiers of the inflammatory reactions. In fact, SGEC patients with Sjögren’s disease are characterized by a unique phenotype which is capable of initiating and perpetuating both innate and adaptive immune responses in the glandular microenvironment. Aberrant expression and function of TLRs and IFN pathways, lymphocyte activating proteins as well as rewired cellular metabolism and antigen-presenting features, shape this distinct auto-antigenic phenotype of SGEC. These discoveries and ideas regarding the regulatory potential of the target SGEC in Sjögren’s disease add a new dimension to our concept of regulatory circuits in autoimmunity.

Introduction

For decades, autoimmune diseases were traditionally studied with a special focus on the immune system and less attention was paid to the roles of target tissues that are being exposed to the immune assault. The ferocity of the immune response, evident once clinical manifestations become visible, made it initially difficult to imagine that an apparently uncontrolled attack on self could be regulated or even initiated by the target tissue. For many common autoimmune diseases, accumulating data unravel and highlight the potential role of the target tissues as orchestrators of the autoimmune responses from early onset to late stages of the diseases.

Salivary epithelium in Sjögren’s disease (SjD) [1, 2], fibroblast-like synoviocytes in rheumatoid arthritis [3, 4], dermal fibroblasts and keratinocytes in Systemic Lupus Erythematosus [5–7], and thyroid follicular cells in autoimmune thyroid disease [8] are only a few examples of such target tissues with major role in regulating autoimmune responses. There is accumulating evidence that the target tissues of these diseases are not innocent bystanders of the autoimmune attack but rather participate in a deleterious dialog with the immune system that leads to their own demise.

In this selective review, using SjD as a model autoimmune disease, we discuss the role of salivary gland epithelial cells (SGECs) as orchestrators of the autoimmune responses that take place in the lesion’s microenvironment. We begin by introducing SGEC and their core molecular differences between health and disease. We then discuss recent evidence that demonstrates how their altered phenotype is translated into autoimmune antigenicity; we focus on the interaction of SGEC with established inflammatory and epigenetic pathways that underlie SjD autoimmunity. Finally, we reflect on the limitations of current evidence and look toward future directions to better understand the unique contribution of SGEC to autoimmune reactivity and potential for treatment interventions. The literature covered here is not exhaustive but, rather, highlights key findings that characterize the current state of the field with respect to salivary gland epithelium.

Sjögren’s disease

SjD is one of the most common autoimmune diseases affecting women around menopause and is characterized by dysfunction and destruction of exocrine glands, mainly of the salivary and lacrimal glands. SjD is featured by a broad spectrum of clinical symptoms ranging from disease confined to the exocrine glands (organ-specific exocrinopathy) to various extraglandular manifestations (systemic disease) and B-cell lymphoma development [1].

A major characteristic of SjD is the presence of dense lymphocytic infiltrating lesions around the epithelial tissue in the salivary glands and the polyclonal/oligoclonal B cell hyperactivity, as suggested by the production of various autoantibodies in the blood (such as antinuclear antibodies, antibodies to Ro/SSA, and La/SSB ribonucleoproteins, to histones and to single-stranded DNA, rheumatoid factors, and cryoglobulins) [9, 10]. These lymphocytic infiltrations are the histological hallmark of SjD [11], and the infiltration score is a central part of the differential diagnosis in SjD [12]. The periepithelial infiltrates consist mainly by CD4+ T cells in early disease and B cells in later stages [13]. Other immune cells such as macrophages, plasmatocytoid, and follicular dendritic cells (DCs) are also often seen at lower percentage [14]. Regarding autoantibodies, anti-SSA/Ro and less often anti-SSB/La antibodies are present in the majority of patients with pSS, and they have been linked to glandular immune activation [15].

To date, it is widely accepted that exposure to specific environmental factors (e.g., a viral infection) in susceptible individuals may play a crucial role, triggering the dysregulation of the immune system and SjD occurrence. The innate immune pathways are activated, involving a subsequent pro-inflammatory cytokine production response and the interferon (IFN) pathway activation [16]. In parallel, the adaptive immune system has a central role in SjD development, as the activation of B-cells and the proliferation of Th1 and Th17 cells contribute to its progression [17]. In this context, disruptions of this delicate balance between SGEC and immune cells leads to salivary gland dysfunction, reduced secretory capacity, and alterations in the glandular microenvironment.

The role of viral infections in SjD

Viral infections can influence the immune system and stimulate the cascade of autoimmunity and the formation of autoantigens through various mechanisms, such as molecular mimicry, bystander activation, epitope spreading, and production of superantigens. Several viruses are suggested to have an effect on autoimmunity—among them are Epstein–Barr virus (EBV), hepatitis C (HCV) virus, and human immunodeficiency virus [18]. SGEC, in particular, have been well known to be targeted by various viruses [19].

EBV DNA has been found increased in the salivary gland as well as in lacrimal gland, tear specimens, and parotid biopsy specimens of patients with SjD [20, 21]. EBV can persist in the human organism in a latent form, allowing the virus to hide in the host SGEC and reactivate under favorable conditions. An EBV microRNA, the ebv-miR-BART13, has been shown to be transferred from B cells to SGEC, where it affects the fluid secretion [22]. Other theories about the effect of EBV on the autoimmune process of SjD include molecular mimicry between the viral EBNA-2 protein and the Ro-60 antigen or the viral EBER-1 and EBER-2 proteins and the La antigen.

The best example of a viral causative role of SjD is probably HCV, a virus with a specific predilection for infecting and replicating in SGEC [23]. A striking association between HCV infection and SjD as well as lymphocytic sialadenitis (Sjogren’s-like disease) has been proven, as anti-HCV was shown to be more prevalent in patients with SjD or chronic sialadenitis than in general population and histological evidence of SjD has been found in patients with chronic HCV infection [24, 25]. Moreover, HCV-RNA has been detected in saliva and in salivary glands from patients with sialadenitis, indicating that HCV infects and replicates in the SGEC of these patients [26].

In a population of HIV-positive patients, about 1/3 had symptoms of dry eyes and/or mouth, while few of them had monocellular infiltrates in their minor salivary gland biopsy meeting the criteria of focus score in SjD [27]. Furthermore, it has been shown that antibodies to proteins of HIV are present in patients with SjD [28].

The B4 Coxsackie viruses (CB4) and C1 (CB1) serotypes are being researched as potential risk factors for developing autoimmune diseases. A previous study has provided evidence that minor salivary gland cells contain viral RNA as well as the main antigenic capsid protein VP1 in SjD patients and not in patients with secondary SjD and controls [29]. Moreover, a cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein was also shown [30].

Core salivary gland epithelium differences between health and SjD

Although the pathogenic pathways underlying SjD have not been yet elucidated, it is well-established that SGEC are central regulators of local autoimmune responses [1]. In recent decades, research has been focused on epithelial cells functions and several lines of immunohistopathologic and in vitro evidence during the last 20 years support the hypothesis that SGEC are not only the target of autoimmunity in SjD patients but may also participate in the initiation and maintenance of the inflammation [31]. Thus far, the importance of the salivary gland epithelium in regulating immune responses in SjD has not been adequately appreciated and the detailed mechanisms merit further investigation.

A milestone in understanding the role of SGEC in autoimmunity was the ability to isolate, expand and long-term culture primary cells derived from salivary gland biopsies during diagnostic work up. In 2002, Dimitriou et al. [32] presented a protocol for the establishment of human non-neoplastic SGEC lines (of ductal type) from a single lobule of labial minor salivary glands for the study of the physiology and pathophysiology of these cells, in a culture free of the influence of other cell types, thus, allowing the evaluation of the constitutive epithelial phenotype and function. In the following years several studies have used this ex vivo approach to show that SGEC under long-term culture conditions retain the ‘activated’ phenotype seen in situ in the patients’ salivary glands’ lesions. To date, it has been shown that SGEC derived from SjD patients are characterized by a unique pro-inflammatory phenotype. Large-scale discovery studies using state-of-the-art technology have provide us with a holistic view of SGEC and their core differences between health and disease.

Moreover, the ‘activated’ SGEC phenotype is characterized by significant morphological and functional changes in SGEC are strongly associated with epithelial cell dysfunction and may serve as key initiators of immune activation in SjD. In comparison to normal SGEC, SjD-SGEC exhibit reduced mitochondrial content, swollen and elongated mitochondria, as well as fewer and aberrant cristae [33]. These alterations (Table 1), regardless of the underlying cause, can induce an immunogenic phenotype and are accompanied by pronounced morphological alterations in situ [34 ]. As explained below, proteomic and transcriptomic analysis has offered insights into the transformation process of SGEC from SjD patients into innate immune cells while uncovering translational modifications associated with metabolic remodeling.

Table 1

Alterations of SGEC in SjD.

CategoryAlterations in salivary epithelial cellsFunctional/pathophysiological implications
Immune-related alterationsInteractions with T cells
– Upregulation of MHC I and II molecules, antigen presentation to CD8+ and CD4+ T cells—Expression of co-stimulatory molecules (CD40, CD80, CD86) supporting T cell activation—Production of IL-6, IL-7, CXCL9, CXCL10, and CXCL11 promoting Th1 and Th17 cell recruitment and retention
Interactions with B cells:
– Secretion of BAFF and APRIL enhancing B cell survival and autoantibody production—Expression of CD40L–CD40 signaling components facilitating local B–T cell collaboration
Interactions with innate immune cells:
– Release of type I interferons (IFN-α/β) and upregulation of interferon-stimulated genes (ISGs; IFI27, MX1, ISG15)—Secretion of chemokines (CCL2, CCL5) attracting monocytes and dendritic cells—Activation of TLR3, TLR7, and TLR9 pathways, amplifying innate immune activation.
Auto-reactive mechanisms:
– Exposure of autoantigens (Ro/SSA, La/SSB) following apoptosis—Autoantigen-loaded exosome secretion—Upregulated Fas/FasL and NF-κB signaling sustaining chronic epithelial activation
SGECs become active participants in local immunity, acting as antigen-presenting and cytokine-producing cells that sustain chronic inflammation, promote ectopic germinal center formation, and drive autoantibody production.
Metabolic alterations– Metabolic rewiring—Mitochondrial dysfunction and damage—Altered lipid metabolism, oxidative stress and DNA damageEnergy imbalance and oxidative stress exacerbate inflammation and secretory dysfunction.
Stress-related alterations– Expression of adrenergic receptors linking sympathetic stress to local responses—Activation of ER stress and unfolded protein response (XBP1, ATF6, CHOP)Sustained stress signaling promotes autoimmune activation, apoptosis and tissue remodeling.

From altered phenotype to autoimmune antigenicity—innate immune function

Similar to other epithelial tissues, SGEC have been proved able to mediate local innate immune responses in the salivary gland epithelium in SjD [35, 36]. Multiple innate immune pathways are likely dysregulated, including the nuclear factor-κB pathway, the inflammasome, and IFN signaling. Indeed, beyond its secretory role, SGEC fulfil innate immune features, which are mainly mediated by the expression of pattern recognition receptors, for example, CD91 molecules [35] and TLRs [36] and the secretion of cytokines [37]. Although the exact initial events that cause innate immune activation of SGEC in SjD are not known, some possibilities include the involvement of pathogen-associated molecular patterns or/and danger/damage-associated molecular patterns or the aberrant expression of endogenous factors (e.g., retroelements) [38–40]

The determination of several types of epithelial tissues that express TLR molecules, such as gastrointestinal, bronchial, and urinary epithelia, supports the notion that the epithelium acts as a frontline defense of the innate immune system [41–43]. Moreover, recent studies reveal that TLRs located on the cell surface also play an essential role in the development of autoimmunity, as demonstrated in rheumatoid arthritis [44], systemic lupus erythematosus [45], and inflammatory bowel diseases [46]. While TLR signaling is required for several different autoimmune diseases, its contribution to SjD initiation and progression remains poorly understood.

TLR signaling seems to have a significant role in the activated phenotype and survival of SGEC. Studies have shown that TLR2, TLR4, and TLR6 are highly expressed in situ by salivary glands of SjD patients but not in controls [47]. Cultured non-neoplastic SGEC derived from SjD patients have been shown to express constitutively high levels of several TLRs, such as TLR1, −2, −3, and −4 compared to control-SGEC lines, as attested by the up-regulation of surface ICAM-1 (intercellular adhesion molecule-1), CD40, and MHC-I expression following treatment with the respective TLR-ligands [36], a fact which supports the intrinsic epithelial activation in SjD [31]. In particular, TLR3 expression by SGEC deserves special attention, since it is significantly higher than other TLRs and is mainly located on the membrane surface [36]. Furthermore, TLR3 signaling has been described to induce apoptotic death of epithelial cells through anoikis [48], production of cytokines that promote inflammatory responses, such as type-I IFNs and BAFF [49, 50], whereas it also augments the expression of Ro/SSA and La/SSB autoantigens in SGEC, suggesting that it might be implicated in autoantigen presentation [49]. The significance of TLR3 signaling in SjD pathogenesis is further supported by in vivo findings in experimental mouse models, where it leads to significant salivary gland hypofunction accompanied by up-regulation of type-I IFN responses and recruitment of B cells, DCs and NK-cells in the submandibular glands [51, 52].

Type I IFN signature and SGEC

IFNs have been implicated in the disruption of the salivary gland epithelium and in pathogenesis of SjD, as reflected by the elevated transcript levels of interferon-stimulated genes in SjD patients [53, 54]. Both type I and II IFNs have been observed in SjD patients versus HC (healthy controls) and SC (sicca controls), respectively, with a predominance of type I IFN signature in peripheral blood and a type II IFN signature in MSG tissues [53]. As mentioned above, epithelial cells themselves can produce type I interferon after stimulation via pattern recognition receptors, as demonstrated in studies of mice and of human SGCEs lines. Activation of the cells by TLR3 ligands could be a major source of type I IFNs within the gland [36]. Differentiated human submandibular gland cells (although debatable of being salivary origin or HELA) were stimulated with mucins or oligosaccharide residues, which were recognized by TLR4, initiating a pro-inflammatory response, cytokine, and interferon production (XCL8, TNF-a, IFN-a, IFN-b, IL-6, and IL-1b) [55]. Moreover, poly(I:C) treatment rapidly up-regulated the mRNA levels of type I IFN and inflammatory cytokines in the submandibular glands of Female New Zealand Black⁄White F1 mice, through TLR3 signaling [56]. Furthermore, TLR-3 stimulation in SGEC causes an immediate and indirect IFN-β-dependent up-regulation of Ro52/TRIM21, creating large quantities of the intracellular autoantigens [49]. Thus, as discussed above, TLR-3 is a molecule at the crossroads of innate and adaptive immunity, as its ligation provides not only signals for IFN production but also active synthesis of the intracellular autoantigens that can eventually prime adaptive immune responses.

Microarray data of salivary gland biopsies from SjD patients revealed an upregulation of interferon I signaling pathway and an increased expression of IFN-inducible genes, including BAFF and IFN-induced transmembrane protein 1, OAS1, IFIT3, IFI6, BST2, TAP1 genes [14, 54]. Thus, in the glandular lesion apart from the infiltrating immune cells, IFNs are found upregulated in SGECs, significantly accounting for the interferon signature of the glands. Similarly, IFN signatures have been observed in other rheumatic diseases, including dermatomyositis (DM), polymyositis, scleroderma, and systemic lupus erythematosus (SLE) [57]. In the salivary glands of patients with SjD, IFNβ is also abundantly produced by immune cells and the salivary gland tissue often has a mixed type I and type II interferon signature [58, 59]. Moreover, IFNλ2 is upregulated in salivary glands of SjD patients compared to individuals with non-SjD sicca symptoms. However, none of the type III IFNs was expressed constitutively in resting SGECs, but only after TLR-3 stimulation, suggesting that the in situ epithelial expression can be attributed to local microenvironment [60]. Whether SGEC-derived type III IFNs notably contribute to salivary gland pathology, either independently or in synergy with other IFNs, remains to be elucidated.

Adaptive immune function of the epithelium: from altered phenotype to lymphocyte activation

As in every tissue, in a normal salivary gland, immune surveillance is supported by the presence of tissue resident immune cells, mainly macrophages and CD8+ T cells [61]. By comparison, the histological hallmark of SjD is lymphocyte infiltration of the salivary gland comprised of CD4+ T cells in early diagnosed cases and B cells in later stages during disease progression. A logical question that has not been fully answered during the last decades is the following: what is driving the immune cells to invade the microenvironment of the salivary gland in SjD? Classical immunology suggests that several immune ‘invitations’ need to be sent systemically and ‘invite’ immune cells to infiltrate the target salivary gland tissues. In SjD, it can easily be postulated that SGECs, through their altered phenotype play this orchestrating role, by expressing and secreting pro-inflammatory molecules.

DCs and SGEC

The timeline of salivary gland infiltration indicates that DCs are among the first cells to infiltrate the tissue of SjD patients at the early stages of the disease [62]. This fact highlights their pivotal role in the immunological landscape of SjD, serving as key players in both the initiation and perpetuation of the autoimmune responses. Their interactions with SGEC, T and B cells, alongside their cytokine production, underline their central role in disease progression.

In the salivary gland microenvironment, SGEC produce pro-inflammatory cytokines (e.g. type I FNs, IL-6, TNF-α) and chemokines (CCL21, CXCL13) that recruit and activate DCs, promoting inflammation [63–65]. They also upregulate adhesion molecules (ICAM-1, vascular cell adhesion molecule-1—VCAM-1) [36] to facilitate DC migration into glandular tissue. Uniquely, SGEC can uptake and present autoantigens via MHC molecules to DCs, activating autoreactive T cells and sustaining autoimmunity. Through toll-like receptors (TLRs), SGEC recognize pathogen-associated molecular patterns and damage-associated molecular patterns [36, 55], further enhancing cytokine production and type-2 conventional dendritic cells (cDC2) recruitment.

In the same glandular milieu, studies have shown that SGEC undergo apoptosis due to chronic inflammation. Following, cDC2s can engulf large amounts of cellular debris released by apoptotic SGEC, leading to the activation of autoimmune responses. The presence of a cDC2 gene signature in the inflamed salivary glands was recently reported by transcriptomic analysis of minor salivary glands from SjD patients. This cDC2 signature was strongly associated with CD4+ T cells [66, 67]. Transcriptional alteration of cDC2s and their aberrant antigen and autoantigen uptake and processing, together with increased proliferation of tissue CD4+ cells, indicate altered antigen presentation of SjD cDC2s. On a functional level, these alterations have been strongly linked to anti-SSA positivity and the presence of type I IFNs [68]. In another similar study, it has been reported that in SjD patients, circulating pDCs have distinct transcriptional profile and are primed to enhance pro-inflammatory cytokine production [69].

While all these findings indicate a strong role for DCs in SjD, what triggers this activated phenotype remains unknown. Thus far, robust research data indicate that SGEC possess full capability of priming DCs toward autoimmune responses. Functional in vivo studies could uncover this potential.

SGEC: crosstalk with CD4+ T cells

The interaction between CD4+ T cells and SGECs is a dynamic immunological dialogue involving multiple cell types, cytokines, and signaling pathways. The initial phase of the crosstalk is mediated by the activation of CD4+ T cells in the periphery, leading to their migration into the salivary glands. Activated CD4+ lymphocytes migrate to salivary glands via chemokine gradients and adhesion mechanisms. Within the gland, SGECs—expressing MHC II, co-stimulatory molecules (CD80/CD86) [70], and cytokines— are able to act as antigen-presenting cells, initiating local immune responses. In turn, CD4+ T cells release pro-inflammatory cytokines like IFN-γ, Il-2, and IL-10, amplifying inflammation and recruiting additional immune cells [63].

CD4+ T subsets

Among the different subsets of CD4+ T cells, Th1, Th2, and Th17 cells are particularly prominent in the development of salivary gland lesions. SjD was originally considered a Th1 signature autoimmune disease, but later it was observed that both Th1 and Th2 cells are drivers of the disease depending on the stage. Evidence suggests that in SjD type-1 and type-2 cytokines are in dynamic balance. Type II microenvironment prevails in low-grade infiltration, while type I pattern increases in patients with definite SjD and patients with advanced lymphocytic infiltration [71].

SGECs can attract Th1 cells through a combination of mechanisms involving chemokine secretion and adhesion molecule expression. SGECs produce chemokines that attract Th1 cells by interacting with chemokine receptors expressed on these cells. Key chemokines expressed by SGEC include CXCL9, CXCL10 [72]. Most of the CD3+ infiltrating lymphocytes in periductal foci express CXCR3, the receptor of these chemokines. SGECs also secrete cytokines like IL-1a, IL-6 and TNF-alpha [63], which promote a Th1 environment. All these molecules create a gradient that guides Th1 cells to the SGECs contributing to salivary gland infiltration by lymphocytes. An additional mechanism used by SGEC to attract Th1 cells is the expression of adhesion molecules that facilitate Th1 cell attachment and migration. These include ICAM-1 and VCAM-1 which Interact with Th1 cells, enhancing adhesion and extravasation into tissue [2, 73]. Th1 cells largely produce IFN-γ and TNF-α, cytokines that in turn activate macrophages, NK cells and CD8+ T cells and maintain cell-mediated immunity [74], as well as IL-18, higher levels of which were noticed in the saliva of SjD patients and NOD mice [75].

Th2 cells, in contrast, are generally thought to promote humoral immunity and are characterized by the secretion of cytokines such as IL-4, IL-5, and IL-13 [76]. These cytokines encourage the activation of B cells and contribute to the chronic inflammation seen in SjD. IL-4, in particular, is a very critical cytokine since a knockout of IL-4 in NOD and NOD.B10-H2b mice was found to restore their salivary gland function [77]. SGECs contribute to Th2 cell recruitment by producing chemokines such as CCL17, CCL22 [78], which bind the Th2-associated receptors CCR4 and CCR8. They also secrete cytokines like IL-33, TSLP, and IL-25 that promote Th2 polarization through direct activation or DC priming [79]. In autoimmune conditions, SGECs expressing MHCII may engage CD4+ T cells in a Th2-skewed cytokine environment, supporting Th2 differentiation. In SjD, this Th2 bias may drive tissue remodeling or fibrosis, highlighting SGECs’ role in shaping immune responses. Understanding the balance between Th1 and Th2 recruitment by SGECs can help elucidate disease mechanisms and uncover therapeutic approaches targeting these pathways.

Th17 cells, which secrete IL-17 and other pro-inflammatory cytokines such as TNF-α, IL-22, and IL-26, are also found in increased numbers in the salivary glands of SjD patients [80]. These cells are particularly implicated in the recruitment of neutrophils and the promotion of an inflammatory environment that exacerbates glandular damage. IL-17 produced by Th17 cells induces the production of other pro-inflammatory cytokines and chemokines, further contributing to the recruitment of immune cells and the development of persistent inflammation. SGECs secrete chemokines like CCL20 and CCL25 forming a gradient guiding Th17 cells into inflamed salivary glands [80]. Several studies have showed elevated levels of IL-17 protein and mRNA in minor salivary glands of SjD patients compared with healthy individuals [81, 82], while IL-17 knockout mice models of SjD did not develop the disease and the elimination of IL-17 in B6.NOD-Aec1Aec2 mice restored normal secretory function and reduced sialadenitis primarily in female mice [83].

Follicular helper T cells (Tfh), which play a pivotal role in B cell activation and differentiation in lymphoid structures, can also be primed by SGEC. Co-cultures of naïve CD4+ T cells and SGECs from both, patients with SjD and controls, was reported to induce naïve CD4+ T differentiation into Tfh cells, as evidenced by their acquisition of a specific phenotype, characterized by Bcl-6, ICOS, and CXCR5 expression and IL-21 secretion, but also by their main functional feature: the capacity to enhance B lymphocytes survival [84]. It has also been reported that in SjD patients, a large number of circulating Tfh cells express CXCR3, which helps them migrate to the inflamed salivary glands, where CXCL10 is expressed [80]. In blood and glandular tissues of SjD patients, the frequency of Tfh cells is higher than in healthy individuals suggesting that these cells contribute to the pathogenesis of the disease by promoting the maturation of B cells [85].

Regulatory T cells (Tregs): The interaction between CD4+ lymphocytes and SGECs also involves regulatory T cells (Tregs), a subset of CD4+ T cells responsible for maintaining immune tolerance and suppressing autoimmune responses. In SjD, there is evidence of a decline in Treg function, leading to an imbalance between effector T cells and Tregs. Treg function declines through mechanisms that disrupt their recruitment, survival, or suppressive activity. This decline contributes to the unchecked activation of autoreactive CD4+ T cells, which in turn exacerbates the autoimmune attack on SGECs [86].

In summary, the interplay between SGEC and the full spectrum of CD4+ subsets, including Th1, Th2, Th17, Tfh, and Tregs, is crucial in the pathogenesis of salivary gland lesions in SjD, with each subset contributing to different aspects of the autoimmune response, tissue damage, and disease progression.

‘Invitation’ to B lymphocytes by SGCEs

B cells are a major immune population of the autoimmune processes in SjD. The fact that autoantibodies are present years (up to 18–20) before the disease onset and the occurrence of monoclonal serum components such as hypergammaglobulinemia and cryoglobulins, underlie the importance of B cells in the disease pathogenesis [87]. The crosstalk between B lymphocytes and SGECs in SjD begins with the recruitment and activation of B cells in the periphery, followed by their infiltration into the salivary glands under the influence of chemokines and adhesion molecules.

By producing various chemokines, including CXCL12 (stromal cell-derived factor-1) and CXCL13 (B lymphocyte chemoattractant), SGEC attract B lymphocytes to the inflamed salivary glands [88]. As mentioned earlier in this article, SGEC can act as antigen-presenting cells. They express major histocompatibility complex (MHC) class II molecules and are capable of presenting autoantigens to B lymphocytes.

A previous study has shown that patients with SjD and anti-La/SSB antibodies presented an active synthesis of the La/SSB protein, which was evidenced by the detection of La/SSB mRNA in the acinar cells of their minor salivary gland biopsies, in contrast to patients lacking these antibodies or those with non-specific sialadenitis [89]. Intriguingly, in SjD, the La/SSB protein undergoes cellular redistribution within acinar epithelial cells, shifting from the nucleoli to the nucleoplasm, cytoplasm, and often to the cell membrane [90, 91]. Moreover, immunogenic apoptosis of epithelial cells has been shown to induce relocalization of Ro/SSA and La/SSB autoantigens to cell surface and apoptotic blebs [92]. This aberrant localization of the two major autoantigens on the cell surface and apoptotic bodies may trigger a localized autoantigen-driven immune response, contributing to the initiation and perpetuation of autoantibody production by B lymphocytes. In line with this, the sustained overexpression of La/SSB in epithelial cells of the affected exocrine glands is thought to underlie the continuous and elevated production of anti-La/SSB autoantibodies in patients with SjD.

Once within the glandular microenvironment, B lymphocytes interact with SGECs expressing immune-related molecules such as MHC II and co-stimulatory molecules facilitating antigen presentation, where SGECs present self-antigens to B lymphocytes, initiating an antigen-specific immune response within the salivary glands. This process activates B lymphocytes, which undergo clonal expansion and differentiation, leading to the production of autoantibodies, particularly against Ro (SSA) and La (SSB) antigens.

As B cells produce autoantibodies against self-antigens, immune complexes deposit in the salivary glands, directly leading to SGEC damage and triggering a cycle of further immune cell recruitment, perpetuating the autoimmune response. Many patients with SjD have been found with elevated circulating immune complexes (CICs) of different immunoglobulin classes showing strong correlation with severe or systemic disease and extraglandular manifestations [93]. Moreover, it has been shown that higher CICs were associated with decreased salivary flow [94]. In another study, however, serum ICs did not correlate with the degree of lymphocytic infiltration in labial salivary glands of SjD patients [95]. Some immune complexes (ICs) can form locally (saliva, glands) and lead to glandular damage. A more recent study has shown that ICs with specific antigens can be identified in saliva from SjD patients [96]. Examples of known SjD autoantigens in saliva ICs of SjD patients are spectrin beta chain, non-erythrocytic 2 and La-related protein 1. Moreover, new IC-antigens were detected in SjD saliva, some of which included neutrophil intracellular proteins (e.g. neutrophil defensin 1, myeloperoxidase, neutrophil elastase, and cathepsin G), which suggests that repeated destruction of neutrophils due to abnormal autoimmunity may lead to exposure of autoantigens. It was also shown that there is limited overlap between saliva and serum IC-antigens, implying that many salivary ICs are formed locally and specifically, rather than being derived from serum or systemic circulation. Last, some IC-antigens showed sequence homology with proteins from the oral microbiome, suggesting that exposure to microbial proteins might lead to cross-reactivity and generation of ICs. Moreover, studies of patients with SjD have shown that TRIM21 can be expressed on the cell surface of antigen-presenting cells, enabling transport of aggregated immunoglobulins and immune complexes into the cell, further inducing type I interferon production and triggering B cell hyperactivity, thereby constituting a vicious inflammatory loop perpetuating disease progression [97].

Furthermore, SGEC produce cytokines such as BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), which can promote the survival, proliferation, and differentiation of B lymphocytes [98, 99]. These cytokines contribute to the formation of ectopic lymphoid structures within the salivary glands, where B lymphocytes organize into germinal centers and perpetuate the autoimmune response. In a study that employed SGEC and B cell cocultures, poly(I:C) induced the secretion of soluble factors by SGEC derived from SjD patients, a fact that enhanced B cell survival [54].

In healthy individuals, B lymphocytes are regulated by various mechanisms to maintain immune tolerance and prevent the production of autoantibodies against self-antigens. In SjD, any impairment of these regulatory mechanisms leads to unchecked B cell activation and differentiation.

The proteomic landscape of SGEC points innate immune phenotype

The first proteomic analysis of primary cultured SGEC was recently performed and revealed important insights about the distinct phenotypes between SjD and control at the protein level [33]. Gene ontology analysis revealed that the protein-cluster with highly abundant proteins in SjD-SGEC was enriched in pathways associated with membrane trafficking, exosome-mediated transport, and exocytosis as well as innate immunity related mainly to neutrophil degranulation. In contrast, the low abundance protein cluster in SjD-SGEC was enriched for proteins regulating the translational process of proteins related to metabolic pathways associated to mitochondria. Collectively, it is clear that SGEC proteome has major differences between SjD and control. These findings substantiate the metamorphosis of SGEC into an innate immune cell and reveal that these cells are translationally shifted toward metabolism rewiring. These metabolic alterations are related mainly to mitochondria and are mirrored in situ with heavy morphological changes [33].

The transcriptomic landscape of SGEC

Deregulation of the salivary gland epithelium in SjD is further supported by significant data at the transcriptome level of SGEC. A comparative transcriptome analysis of gene expression profiles in long-term cultured SGEC lines derived from SjD patients and controls [100] revealed that SGEC lines from SjD patients with severe histopathologic lesions are characterized by a distinct pro-inflammatory molecular signature. Several differentially expressed genes were identified between the SjD-SGEC lines and the control SGECs. Among them, the expression of IL-1b, VERSICAN, and PYCARD/ASC was found elevated, while that of NFKBIA (IkBa) was reduced. The pathway analysis of DEGs using ingenuity pathway analysis (IPA), revealed the perturbation of various inflammation-related pathways, including those of interferon signaling, inflammasome, IL-1b, IL-6, IL-8 signaling, NF-κB and pattern recognition receptors, as well as metabolism-related signaling pathways primarily in the SjD-SGEC lines, such as adipogenesis pathway, AMPK and PPAR signaling [101].

In another similar study, total RNAseq profiling was performed using sorted SGEC from SjD patients and control subjects. IFI6, VGLL2, and ZNF879 were the most significantly upregulated genes, and CCL22 was one of the most significantly downregulated genes. The functional enrichment analysis highlighted an over-representation of the IFN signaling pathway, including OAS1, IFIT3, IFI6, BST2, TAP1 genes, B-cell development pathway (BAFF-R, (HLA-DRA), and IL-7 signaling pathway (including IL-7 and STAT1 genes) [54]. These molecules are known to mediate lymphoid cell homing, antigen presentation, neovascularization, and the amplification of epithelial–immune cells interactions. Together, these data clearly indicate that SGECs’ activated phenotype is sustained in vitro, outside the tissue microenvironment and this strongly suggests that the cells are capable of initiating and regulating the autoimmune response in salivary glands.

Abnormal epigenetic modifications in SjD

Over the last few years, epigenetic alterations including changes in DNA methylation, histone modifications, and microRNA expression have been described in SjD and suggest a key role for the pathogenesis of the disease [102, 103]. During the progression of the disease, significant epigenetic modifications have been observed in both immune cells and SGEC, indicating a robust association with autoimmune responses [104]. An epigenetic analysis of labial salivary glands in SjD patients revealed distinct methylation patterns at CpG sites with differential methylation between SjD subgroups, providing evidence for the involvement of epigenetic factors in the heterogeneity of SjD [105]. In a previous study, it was shown that the decreased mRNA levels of the proteins involved in the IRE1alpha/XBP-1 pathway was attributed to the hypermethylation of their promoters and was consistent with chronic ER stress, which may explain the impaired salivary gland function in SjD patients [106]. In another study, DNA methylation reduction was associated with lymphocyte infiltration, and demethylated acini were predominantly found in anti-SSB/La positive SjD patients, as a result of the differential DNA methylation status at the SSB gene promoters between anti-SSB/La positive and negative patients. This led to SSB overexpression at both transcriptional and protein levels in SGCEs of the patients [107]. These data highlight the importance of DNA methylation in the pathophysiology of the SjD and raises questions about the epigenetic deregulation in SjD patients.

Stress and SGEC

The influence of psychological stress on the development or the course of autoimmune disorders has been discussed for a long time and has aroused increasingly widespread interest and concern in the medical community. Indeed, based on epidemiological studies, stress has been suggested to precede AIDs occurrence and to exacerbate symptoms. There is rich literature showing that stress is associated with disease onset, and disease exacerbations in SjD [108–111]. Experiencing more than one negative stressful life event in the year preceding the onset of Sjögren’s syndrome increases 4-fold the risk of disease onset compared to healthy controls. In a recent study, Hsu et al.[112] showed that subjects with a history of PTSD were significantly more likely to develop autoimmune conditions. In fact, they were six times more likely to develop SjD compared to those without PTSD. A major question that remains unanswered is: What are the mechanisms that translate stress into autoimmune responses?

In an attempt to address this question, our group published recently a study investigating the involvement of epinephrine, a major stress hormone, in the pathophysiology of SGEC in SjD [113]. One major finding was that SGEC overexpress beta adrenergic receptors in the salivary gland lesion of SjD patients compared to SGEC from controls. The high expression levels of these receptors by SGEC along with elevated intracellular cAMP suggest an altered adrenergic signaling pathway in SjD. In fact, when SjD SGEC were stimulated with epinephrine, they secreted IL6. Importantly, the effects of adrenergic stress on SGEC are mediated by the cell’s endoplasmic reticulum (ER) stress machinery.

ER is a major part of SGEC phenotype in SjD and data show that ER stress can induce immunogenic apoptosis leading to cell surface and apoptotic blebs relocalization of Ro/SSA and La/SSB autoantigens [92]. The ER chaperone ERdj5, a key molecule for the processing of misfolded proteins in the ER, has been also found elevated in the minor salivary glands of SjD patients, with stain intensity correlated to inflammatory lesion severity and anti-SSA/Ro positivity [114]. Remarkably, ablation of ERdj5 in mice results in an activated ER-stress response, evident by the upregulation of the alternatively spliced form of XBP1 within the salivary glands [115].

The effects of psychological stress on autoimmunity are still poorly defined and SjD appears to be a robust model for this investigation. The published evidence so far indicates that SGEC are pivotal components of this mechanism and represent a strong candidate for further studies in SjD.

Unanswered questions and future directions

The emergence of new molecular biology tools and technologies like single-cell omics, has provided a transformative, high-definition view of the cellular populations that exist in the salivary glands of SjD patients but has also generated many unanswered questions for the research community:

  • What are the mechanisms of epithelial cell dysfunction? Future research in Sjögren’s needs to focus on comprehensive elucidation of the molecular and cellular mechanisms by which SGECs contribute to autoimmunity. We need a better understanding of the disease in respect to glandular microenvironment in a more detailed and chronological order. It is necessary to identify the very early events in order to design precision and efficient therapies before the full spectrum of the disease develops. This includes investigating how these cells initiate and perpetuate immune responses through the expression of autoantigens, pro-inflammatory cytokines, and adhesion molecules. Understanding the role of SGECs in initiating autoimmunity and activation of autoreactive lymphocytes could reveal novel therapeutic targets to halt disease progression, beyond current immunotherapies.

  • How do cells in the contemporary single-cell landscape reflect those detected by traditional microscopy methods? Advances in single-cell RNA sequencing and spatial omics have already provided unprecedented insights in various diseases, predominantly in cancer. In SjD, there is an urgent need for mapping the glandular microenvironment and generating a Sjogren’s salivary gland atlas of different stages of the disease progression to help us uncover the full spectrum of events from early beginning to more severe lesions. This spatiotemporal information about SGECs and their interactions with immune cells in the salivary gland microenvironment will help identify specific epithelial cell subsets that drive inflammation and fibrosis, as well as uncover signaling pathways involved in glandular dysfunction. This knowledge could lead to personalized treatment strategies tailored to distinct disease endotypes.

  • How much significance should we place and what is the importance of focusing on SGEC-targeting therapies and regenerative approaches? Currently, SjD research exists in silos, which hampers our ability to elucidate the interplay and underlying molecular mechanisms by which target SGECs yield biological changes. Most biological therapies are targeted against immune cells and less, if any, are designed to target the host salivary gland tissue. A key future direction is the development of therapies that directly modulate SGEC function to restore glandular homeostasis. This includes exploring biologics, small molecules, or gene therapies that can suppress aberrant immune activation while promoting epithelial cell survival and regeneration. Additionally, stem cell-based approaches to repair or replace damaged salivary gland tissue may offer long-term solutions for restoring saliva production and improving patients’ quality of life.

Conclusion

The crosstalk between SGEC and immune cells in SjD is a complex and dynamic process involving multiple signaling pathways, cytokines, and cell populations (Fig. 1). Understanding the molecular mechanisms governing this interaction is essential for developing targeted therapies to halt or reverse the progression of the disease. By targeting specific molecules or signaling pathways involved in this crosstalk, it may be possible to restore immune tolerance and ameliorate the devastating consequences of Sjögren’s. Further research in this area will undoubtedly shed light on new therapeutic avenues for patients suffering from this challenging autoimmune disorder.

Crosstalk between salivary gland epithelial cells (SGECs) and immune populations in Sjögren’s disease. Intrinsically activated SGEC release IL-6, IFN-β, and chemokines to activate CD4 lymphocytes and prime T follicular helper (Tfh) cells, while low TGF-β/IL-10 suppresses Treg functions. SGECs secrete exosomes and apoptotic debris containing ncRNAs and autoantigens (e.g. Ro/SSA, La/SSB), while activating dendritic cells. Chemokines (CXCL9-11) recruit innate immune cells, while BAFF/APRIL from SGECs drive B cell activation. Autoantibody production by B cells is facilitated by autoantigens derived from apoptotic SGECs and exosomal cargo. Intrinsically activated SGECs are vulnerable to sympathetic stress promoting ER stress and IL-6 release. Together, these interactions both trigger and sustain glandular inflammation and epithelial damage (Abbreviations: ER, endoplasmic reticulum; Tfh, T follicular helper; Treg, regulatory T cell; ncRNA, non-coding RNA).
Figure 1

Crosstalk between salivary gland epithelial cells (SGECs) and immune populations in Sjögren’s disease. Intrinsically activated SGEC release IL-6, IFN-β, and chemokines to activate CD4 lymphocytes and prime T follicular helper (Tfh) cells, while low TGF-β/IL-10 suppresses Treg functions. SGECs secrete exosomes and apoptotic debris containing ncRNAs and autoantigens (e.g. Ro/SSA, La/SSB), while activating dendritic cells. Chemokines (CXCL9-11) recruit innate immune cells, while BAFF/APRIL from SGECs drive B cell activation. Autoantibody production by B cells is facilitated by autoantigens derived from apoptotic SGECs and exosomal cargo. Intrinsically activated SGECs are vulnerable to sympathetic stress promoting ER stress and IL-6 release. Together, these interactions both trigger and sustain glandular inflammation and epithelial damage (Abbreviations: ER, endoplasmic reticulum; Tfh, T follicular helper; Treg, regulatory T cell; ncRNA, non-coding RNA).

Acknowledgements

Not applicable.

Author contributions

Maria Filika (Conceptualization, Writing—original draft, Writing—review and editing), and Stergios Katsiougiannis (Conceptualization, Funding acquisition, Writing—review & editing)

Funding

European Alliance of Associations for Rheumatology (EULAR). 2025 Research Voucher Award, ID:Q424RSV203.

Data availability

Not applicable for this review article.

Ethical approval

Not applicable.

References

1

Moutsopoulos
 
HM
.
Sjogren’s syndrome: a forty-year scientific journey
.
J Autoimmun
 
2014
,
51
,
1
–
9
.

2

Kapsogeorgou
 
EK
,
Dimitriou
 
ID
,
Abu-Helu
 
RF
,
Moutsopoulos
 
HM
,
Manoussakis
 
MN
.
Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjogren’s syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells
.
Clin Exp Immunol
 
2001
,
124
,
126
–
33
.

3

Bartok
 
B
,
Firestein
 
GS
.
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis
.
Immunol Rev
 
2010
,
233
,
233
–
55
.

4

Bottini
 
N
,
Firestein
 
GS
.
Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors
.
Nat Rev Rheumatol
 
2013
,
9
,
24
–
33
.

5

Stannard
 
JN
,
Kahlenberg
 
JM
.
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus
.
Curr Opin Rheumatol
 
2016
,
28
,
453
–
9
.

6

Billi
 
AC
,
Ma
 
F
,
Plazyo
 
O
,
Gharaee-Kermani
 
M
,
Wasikowski
 
R
,
Hile
 
GA
, et al.  
Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation
.
Sci Transl Med
 
2022
,
14
,
eabn2263
.

7

Kahlenberg
 
JM
.
Rethinking the pathogenesis of cutaneous lupus
.
J Invest Dermatol
 
2021
,
141
,
32
–
5
.

8

Huang
 
N
,
Liu
 
D
,
Lian
 
Y
,
Chi
 
H
,
Qiao
 
J
.
Immunological microenvironment alterations in follicles of patients with autoimmune thyroiditis
.
Front Immunol
 
2021
,
12
,
770852
.

9

Routsias
 
JG
,
Tzioufas
 
AG
.
Autoimmune response and target autoantigens in Sjogren’s syndrome
.
Eur J Clin Invest
 
2010
,
40
,
1026
–
36
.

10

Goules
 
AV
,
Tzioufas
 
AG
.
Primary Sjӧgren’s syndrome: clinical phenotypes, outcome and the development of biomarkers
.
Autoimmun Rev
 
2016
,
15
,
695
–
703
.

11

Skopouli
 
FN
,
Dafni
 
U
,
Ioannidis
 
JP
,
Moutsopoulos
 
HM
.
Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome
.
Semin Arthritis Rheum
 
2000
,
29
,
296
–
304
.

12

Greenspan
 
JS
,
Daniels
 
TE
,
Talal
 
N
,
Sylvester
 
RA
.
The histopathology of Sjogren’s syndrome in labial salivary gland biopsies
.
Oral Surg Oral Med Oral Pathol
 
1974
,
37
,
217
–
29
.

13

Christodoulou
 
MI
,
Kapsogeorgou
 
EK
,
Moutsopoulos
 
HM
.
Characteristics of the minor salivary gland infiltrates in Sjogren’s syndrome
.
J Autoimmun
 
2010
,
34
,
400
–
7
.

14

Gottenberg
 
JE
,
Cagnard
 
N
,
Lucchesi
 
C
,
Letourneur
 
F
,
Mistou
 
S
,
Lazure
 
T
, et al.  
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome
.
Proc Natl Acad Sci U S A
 
2006
,
103
,
2770
–
5
.

15

Zampeli
 
E
,
Mavrommati
 
M
,
Moutsopoulos
 
HM
,
Skopouli
 
FN
.
Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations
.
Clin Exp Rheumatol
 
2020
,
38 Suppl 126
,
134
–
41
.

16

Shimizu
 
T
,
Nakamura
 
H
,
Kawakami
 
A
.
Role of the innate immunity signaling pathway in the pathogenesis of Sjogren’s syndrome
.
Int J Mol Sci
 
2021
,
22
,
3090
.

17

Chivasso
 
C
,
Sarrand
 
J
,
Perret
 
J
,
Delporte
 
C
,
Soyfoo
 
MS
.
The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjogren’s syndrome
.
Int J Mol Sci
 
2021
,
22
,
658
.

18

Smatti
 
MK
,
Cyprian
 
FS
,
Nasrallah
 
GK
,
Al Thani
 
AA
,
Almishal
 
RO
,
Yassine
 
HM
.
Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms
.
Viruses
 
2019
,
11
,
762
.

19

Igoe
 
A
,
Scofield
 
RH
.
Autoimmunity and infection in Sjogren’s syndrome
.
Curr Opin Rheumatol
 
2013
,
25
,
480
–
7
.

20

Fox
 
RI
,
Pearson
 
G
,
Vaughan
 
JH
.
Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren’s syndrome
.
J Immunol
 
1986
,
137
,
3162
–
8
.

21

Saito
 
I
,
Servenius
 
B
,
Compton
 
T
,
Fox
 
RI
.
Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren’s syndrome
.
J Exp Med
 
1989
,
169
,
2191
–
8
.

22

Gallo
 
A
,
Jang
 
SI
,
Ong
 
HL
,
Perez
 
P
,
Tandon
 
M
,
Ambudkar
 
I
, et al.  
Targeting the Ca(2+) sensor STIM1 by exosomal transfer of Ebv-miR-BART13-3p is associated with Sjogren’s syndrome
.
EBioMedicine
 
2016
,
10
,
216
–
26
.

23

Ramos-Casals
 
M
,
De Vita
 
S
,
Tzioufas
 
AG
.
Hepatitis C virus, Sjogren’s syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer
.
Autoimmun Rev
 
2005
,
4
,
8
–
15
.

24

De Bandt
 
M
,
Ribard
 
P
,
Meyer
 
O
,
Palazzo
 
E
,
Kahn
 
MF
,
Elias
 
A
, et al.  
Type II IgM monoclonal cryoglobulinemia and hepatitis C virus infection
.
Clin Exp Rheumatol
 
1991
,
9
,
659
–
60
.

25

Haddad
 
J
,
Deny
 
P
,
Munz-Gotheil
 
C
,
Ambrosini
 
JC
,
Trinchet
 
JC
,
Pateron
 
D
, et al.  
Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease
.
Lancet
 
1992
,
339
,
321
–
3
.

26

Arrieta
 
JJ
,
Rodriguez-Inigo
 
E
,
Ortiz-Movilla
 
N
,
Bartolome
 
J
,
Pardo
 
M
,
Manzarbeitia
 
F
, et al.  
In situ detection of hepatitis C virus RNA in salivary glands
.
Am J Pathol
 
2001
,
158
,
259
–
64
.

27

Kordossis
 
T
,
Paikos
 
S
,
Aroni
 
K
,
Kitsanta
 
P
,
Dimitrakopoulos
 
A
,
Kavouklis
 
E
, et al.  
Prevalence of Sjogren’s-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology
.
Br J Rheumatol
 
1998
,
37
,
691
–
5
.

28

Coll
 
J
,
Palazon
 
J
,
Yazbeck
 
H
,
Gutierrez
 
J
,
Aubo
 
C
,
Benito
 
P
, et al.  
Antibodies to human immunodeficiency virus (HIV-1) in autoimmune diseases: primary Sjogren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroid diseases
.
Clin Rheumatol
 
1995
,
14
,
451
–
7
.

29

Triantafyllopoulou
 
A
,
Tapinos
 
N
,
Moutsopoulos
 
HM
.
Evidence for coxsackievirus infection in primary Sjogren’s syndrome
.
Arthritis Rheum
 
2004
,
50
,
2897
–
902
.

30

Stathopoulou
 
EA
,
Routsias
 
JG
,
Stea
 
EA
,
Moutsopoulos
 
HM
,
Tzioufas
 
AG
.
Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein
.
Clin Exp Immunol
 
2005
,
141
,
148
–
54
.

31

Manoussakis
 
MN
,
Kapsogeorgou
 
EK
.
The role of intrinsic epithelial activation in the pathogenesis of Sjogren’s syndrome
.
J Autoimmun
 
2010
,
35
,
219
–
24
.

32

Dimitriou
 
ID
,
Kapsogeorgou
 
EK
,
Abu-Helu
 
RF
,
Moutsopoulos
 
HM
,
Manoussakis
 
MN
.
Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells
.
Eur J Oral Sci
 
2002
,
110
,
21
–
30
.

33

Katsiougiannis
 
S
,
Stergiopoulos
 
A
,
Moustaka
 
K
,
Havaki
 
S
,
Samiotaki
 
M
,
Stamatakis
 
G
, et al.  
Salivary gland epithelial cell in Sjogren’s syndrome: metabolic shift and altered mitochondrial morphology toward an innate immune cell function
.
J Autoimmun
 
2023
,
136
,
103014
.

34

Katsiougiannis
 
S
,
Tenta
 
R
,
Skopouli
 
FN
.
Autoimmune epithelitis (Sjogren’s syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity
.
J Autoimmun
 
2019
,
104
,
102335
.

35

Bourazopoulou
 
E
,
Kapsogeorgou
 
EK
,
Routsias
 
JG
,
Manoussakis
 
MN
,
Moutsopoulos
 
HM
,
Tzioufas
 
AG
.
Functional expression of the alpha 2-macroglobulin receptor CD91 in salivary gland epithelial cells
.
J Autoimmun
 
2009
,
33
,
141
–
6
.

36

Spachidou
 
MP
,
Bourazopoulou
 
E
,
Maratheftis
 
CI
,
Kapsogeorgou
 
EK
,
Moutsopoulos
 
HM
,
Tzioufas
 
AG
, et al.  
Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren’s syndrome
.
Clin Exp Immunol
 
2007
,
147
,
497
–
503
.

37

Riviere
 
E
,
Pascaud
 
J
,
Virone
 
A
,
Dupre
 
A
,
Ly
 
B
,
Paoletti
 
A
, et al.  
Interleukin-7/interferon axis drives T cell and salivary gland epithelial cell interactions in Sjogren’s syndrome
.
Arthritis Rheumatol
 
2021
,
73
,
631
–
40
.

38

Ming
 
B
,
Zhu
 
Y
,
Zhong
 
J
,
Dong
 
L
.
Immunopathogenesis of Sjogren’s syndrome: current state of DAMPs
.
Semin Arthritis Rheum
 
2022
,
56
,
152062
.

39

Brennan
 
MT
,
Mougeot
 
JL
.
Alu retroelement-associated autoimmunity in Sjogren’s syndrome
.
Oral Dis
 
2016
,
22
,
345
–
7
.

40

Mavragani
 
CP
,
Nezos
 
A
,
Sagalovskiy
 
I
,
Seshan
 
S
,
Kirou
 
KA
,
Crow
 
MK
.
Defective regulation of L1 endogenous retroelements in primary Sjogren’s syndrome and systemic lupus erythematosus: role of methylating enzymes
.
J Autoimmun
 
2018
,
88
,
75
–
82
.

41

Bocker
 
U
,
Yezerskyy
 
O
,
Feick
 
P
,
Manigold
 
T
,
Panja
 
A
,
Kalina
 
U
, et al.  
Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression
.
Int J Colorectal Dis
 
2003
,
18
,
25
–
32
.

42

Hertz
 
CJ
,
Wu
 
Q
,
Porter
 
EM
,
Zhang
 
YJ
,
Weismuller
 
KH
,
Godowski
 
PJ
, et al.  
Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2
.
J Immunol
 
2003
,
171
,
6820
–
6
.

43

Li
 
M
,
Zhou
 
Y
,
Feng
 
G
,
Su
 
SB
.
The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases
.
Curr Mol Med
 
2009
,
9
,
365
–
74
.

44

Brentano
 
F
,
Schorr
 
O
,
Gay
 
RE
,
Gay
 
S
,
Kyburz
 
D
.
RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3
.
Arthritis Rheum
 
2005
,
52
,
2656
–
65
.

45

Wu
 
Y
,
He
 
S
,
Bai
 
B
,
Zhang
 
L
,
Xue
 
L
,
Lin
 
Z
, et al.  
Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation
.
Cell Mol Immunol
 
2016
,
13
,
379
–
90
.

46

Sipos
 
F
,
Furi
 
I
,
Constantinovits
 
M
,
Tulassay
 
Z
,
Muzes
 
G
.
Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease
.
World J Gastroenterol
 
2014
,
20
,
12713
–
21
.

47

Kwok
 
SK
,
Cho
 
ML
,
Her
 
YM
,
Oh
 
HJ
,
Park
 
MK
,
Lee
 
SY
, et al.  
TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren’s syndrome
.
Arthritis Res Ther
 
2012
,
14
,
R64
.

48

Manoussakis
 
MN
,
Spachidou
 
MP
,
Maratheftis
 
CI
.
Salivary epithelial cells from Sjogren’s syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation
.
J Autoimmun
 
2010
,
35
,
212
–
8
.

49

Kyriakidis
 
NC
,
Kapsogeorgou
 
EK
,
Gourzi
 
VC
,
Konsta
 
OD
,
Baltatzis
 
GE
,
Tzioufas
 
AG
.
Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway
.
Clin Exp Immunol
 
2014
,
178
,
548
–
60
.

50

Ittah
 
M
,
Miceli-Richard
 
C
,
Gottenberg
 
JE
,
Sellam
 
J
,
Eid
 
P
,
Lebon
 
P
, et al.  
Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways
.
Eur J Immunol
 
2008
,
38
,
1058
–
64
.

51

Nandula
 
SR
,
Dey
 
P
,
Corbin
 
KL
,
Nunemaker
 
CS
,
Bagavant
 
H
,
Deshmukh
 
US
.
Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling
.
J Oral Pathol Med
 
2013
,
42
,
66
–
72
.

52

Nandula
 
SR
,
Scindia
 
YM
,
Dey
 
P
,
Bagavant
 
H
,
Deshmukh
 
US
.
Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjogren’s syndrome-like disease
.
Oral Dis
 
2011
,
17
,
801
–
7
.

53

Nezos
 
A
,
Gravani
 
F
,
Tassidou
 
A
,
Kapsogeorgou
 
EK
,
Voulgarelis
 
M
,
Koutsilieris
 
M
, et al.  
Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis
.
J Autoimmun
 
2015
,
63
,
47
–
58
.

54

Riviere
 
E
,
Pascaud
 
J
,
Tchitchek
 
N
,
Boudaoud
 
S
,
Paoletti
 
A
,
Ly
 
B
, et al.  
Salivary gland epithelial cells from patients with Sjogren’s syndrome induce B-lymphocyte survival and activation
.
Ann Rheum Dis
 
2020
,
79
,
1468
–
77
.

55

Barrera
 
MJ
,
Aguilera
 
S
,
Veerman
 
E
,
Quest
 
AF
,
Diaz-Jimenez
 
D
,
Urzua
 
U
, et al.  
Salivary mucins induce a Toll-like receptor 4-mediated pro-inflammatory response in human submandibular salivary cells: are mucins involved in Sjogren’s syndrome?
 
Rheumatology (Oxford)
 
2015
,
54
,
1518
–
27
.

56

Deshmukh
 
US
,
Nandula
 
SR
,
Thimmalapura
 
PR
,
Scindia
 
YM
,
Bagavant
 
H
.
Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function
.
J Oral Pathol Med
 
2009
,
38
,
42
–
7
.

57

Higgs
 
BW
,
Liu
 
Z
,
White
 
B
,
Zhu
 
W
,
White
 
WI
,
Morehouse
 
C
, et al.  
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
.
Ann Rheum Dis
 
2011
,
70
,
2029
–
36
.

58

Fox
 
RI
.
Epidemiology, pathogenesis, animal models, and treatment of Sjogren’s syndrome
.
Curr Opin Rheumatol
 
1994
,
6
,
501
–
8
.

59

Hall
 
JC
,
Casciola-Rosen
 
L
,
Berger
 
AE
,
Kapsogeorgou
 
EK
,
Cheadle
 
C
,
Tzioufas
 
AG
, et al.  
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases
.
Proc Natl Acad Sci U S A
 
2012
,
109
,
17609
–
14
.

60

Apostolou
 
E
,
Kapsogeorgou
 
EK
,
Konsta
 
OD
,
Giotakis
 
I
,
Saridaki
 
MI
,
Andreakos
 
E
, et al.  
Expression of type III interferons (IFNlambdas) and their receptor in Sjogren’s syndrome
.
Clin Exp Immunol
 
2016
,
186
,
304
–
12
.

61

Stolp
 
B
,
Thelen
 
F
,
Ficht
 
X
,
Altenburger
 
LM
,
Ruef
 
N
,
Inavalli
 
V
, et al.  
Salivary gland macrophages and tissue-resident CD8(+) T cells cooperate for homeostatic organ surveillance
.
Sci Immunol
 
2020
,
5
,
eaaz4371
.

62

Zhao
 
J
,
Kubo
 
S
,
Nakayamada
 
S
,
Shimajiri
 
S
,
Zhang
 
X
,
Yamaoka
 
K
, et al.  
Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjogren’s syndrome
.
Mod Rheumatol
 
2016
,
26
,
716
–
24
.

63

Fox
 
RI
,
Kang
 
HI
,
Ando
 
D
,
Abrams
 
J
,
Pisa
 
E
.
Cytokine mRNA expression in salivary gland biopsies of Sjogren’s syndrome
.
J Immunol
 
1994
,
152
,
5532
–
9
.

64

Kawanami
 
T
,
Sawaki
 
T
,
Sakai
 
T
,
Miki
 
M
,
Iwao
 
H
,
Nakajima
 
A
, et al.  
Skewed production of IL-6 and TGFbeta by cultured salivary gland epithelial cells from patients with Sjogren’s syndrome
.
PLoS One
 
2012
,
7
,
e45689
.

65

Xanthou
 
G
,
Polihronis
 
M
,
Tzioufas
 
AG
,
Paikos
 
S
,
Sideras
 
P
,
Moutsopoulos
 
HM
.
Lymphoid” chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren’s syndrome patients: possible participation in lymphoid structure formation
.
Arthritis Rheum
 
2001
,
44
,
408
–
18
.

66

Cheng
 
C
,
Zhou
 
J
,
Chen
 
R
,
Shibata
 
Y
,
Tanaka
 
R
,
Wang
 
J
, et al.  
Predicted disease-specific immune infiltration patterns decode the potential mechanisms of long non-coding RNAs in primary Sjogren’s syndrome
.
Front Immunol
 
2021
,
12
,
624614
.

67

Oyelakin
 
A
,
Horeth
 
E
,
Song
 
EC
,
Min
 
S
,
Che
 
M
,
Marzullo
 
B
, et al.  
Transcriptomic and network analysis of minor salivary glands of patients with primary Sjogren’s syndrome
.
Front Immunol
 
2020
,
11
,
606268
.

68

Lopes
 
AP
,
Hillen
 
MR
,
Hinrichs
 
AC
,
Blokland
 
SL
,
Bekker
 
CP
,
Pandit
 
A
, et al.  
Deciphering the role of cDC2s in Sjogren’s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity
.
Ann Rheum Dis
 
2023
,
82
,
374
–
83
.

69

Hillen
 
MR
,
Pandit
 
A
,
Blokland
 
SLM
,
Hartgring
 
SAY
,
Bekker
 
CPJ
,
van der Heijden
 
EHM
, et al.  
Plasmacytoid DCs from patients with Sjogren’s syndrome are transcriptionally primed for enhanced pro-inflammatory cytokine production
.
Front Immunol
 
2019
,
10
,
2096
.

70

Tsunawaki
 
S
,
Nakamura
 
S
,
Ohyama
 
Y
,
Sasaki
 
M
,
Ikebe-Hiroki
 
A
,
Hiraki
 
A
, et al.  
Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren’s syndrome
.
J Rheumatol
 
2002
,
29
,
1884
–
96
.

71

Mitsias
 
DI
,
Tzioufas
 
AG
,
Veiopoulou
 
C
,
Zintzaras
 
E
,
Tassios
 
IK
,
Kogopoulou
 
O
, et al.  
The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren’s syndrome
.
Clin Exp Immunol
 
2002
,
128
,
562
–
8
.

72

Ogawa
 
N
,
Ping
 
L
,
Zhenjun
 
L
,
Takada
 
Y
,
Sugai
 
S
.
Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren’s syndrome
.
Arthritis Rheum
 
2002
,
46
,
2730
–
41
.

73

Saito
 
I
,
Terauchi
 
K
,
Shimuta
 
M
,
Nishiimura
 
S
,
Yoshino
 
K
,
Takeuchi
 
T
, et al.  
Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren’s syndrome
.
J Clin Lab Anal
 
1993
,
7
,
180
–
7
.

74

Pflugfelder
 
SC
,
Corrales
 
RM
,
de Paiva
 
CS
.
T helper cytokines in dry eye disease
.
Exp Eye Res
 
2013
,
117
,
118
–
25
.

75

Delaleu
 
N
,
Immervoll
 
H
,
Cornelius
 
J
,
Jonsson
 
R
.
Biomarker profiles in serum and saliva of experimental Sjogren’s syndrome: associations with specific autoimmune manifestations
.
Arthritis Res Ther
 
2008
,
10
,
R22
.

76

Kokubo
 
K
,
Onodera
 
A
,
Kiuchi
 
M
,
Tsuji
 
K
,
Hirahara
 
K
,
Nakayama
 
T
.
Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis
.
Front Immunol
 
2022
,
13
,
945063
.

77

Brayer
 
JB
,
Cha
 
S
,
Nagashima
 
H
,
Yasunari
 
U
,
Lindberg
 
A
,
Diggs
 
S
, et al.  
IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren’s syndrome
.
Scand J Immunol
 
2001
,
54
,
133
–
40
.

78

Moriyama
 
M
,
Hayashida
 
JN
,
Toyoshima
 
T
,
Ohyama
 
Y
,
Shinozaki
 
S
,
Tanaka
 
A
, et al.  
Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjogren’s syndrome
.
Clin Exp Immunol
 
2012
,
169
,
17
–
26
.

79

Dong
 
Y
,
Wang
 
T
,
Wu
 
H
.
The role of cytokines from salivary gland epithelial cells in the immunopathology of Sjogren’s syndrome
.
Front Immunol
 
2024
,
15
,
1443455
.

80

Verstappen
 
GM
,
Corneth
 
OBJ
,
Bootsma
 
H
,
Kroese
 
FGM
.
Th17 cells in primary Sjogren’s syndrome: pathogenicity and plasticity
.
J Autoimmun
 
2018
,
87
,
16
–
25
.

81

Katsifis
 
GE
,
Rekka
 
S
,
Moutsopoulos
 
NM
,
Pillemer
 
S
,
Wahl
 
SM
.
Systemic and local interleukin-17 and linked cytokines associated with Sjogren’s syndrome immunopathogenesis
.
Am J Pathol
 
2009
,
175
,
1167
–
77
.

82

Sakai
 
A
,
Sugawara
 
Y
,
Kuroishi
 
T
,
Sasano
 
T
,
Sugawara
 
S
.
Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18
.
J Immunol
 
2008
,
181
,
2898
–
906
.

83

Voigt
 
A
,
Esfandiary
 
L
,
Wanchoo
 
A
,
Glenton
 
P
,
Donate
 
A
,
Craft
 
WF
, et al.  
Sexual dimorphic function of IL-17 in salivary gland dysfunction of the C57BL/6.NOD-Aec1Aec2 model of Sjogren’s syndrome
.
Sci Rep
 
2016
,
6
,
38717
.

84

Gong
 
YZ
,
Nititham
 
J
,
Taylor
 
K
,
Miceli-Richard
 
C
,
Sordet
 
C
,
Wachsmann
 
D
, et al.  
Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren’s syndrome
.
J Autoimmun
 
2014
,
51
,
57
–
66
.

85

Jin
 
L
,
Yu
 
D
,
Li
 
X
,
Yu
 
N
,
Li
 
X
,
Wang
 
Y
, et al.  
CD4+ CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren’s syndrome
.
Int J Clin Exp Pathol
 
2014
,
7
,
1988
–
96
.

86

Christodoulou
 
MI
,
Kapsogeorgou
 
EK
,
Moutsopoulos
 
NM
,
Moutsopoulos
 
HM
.
Foxp3+ T-regulatory cells in Sjogren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors
.
Am J Pathol
 
2008
,
173
,
1389
–
96
.

87

Theander
 
E
,
Jonsson
 
R
,
Sjostrom
 
B
,
Brokstad
 
K
,
Olsson
 
P
,
Henriksson
 
G
.
Prediction of Sjogren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling
.
Arthritis Rheumatol
 
2015
,
67
,
2427
–
36
.

88

Barone
 
F
,
Bombardieri
 
M
,
Rosado
 
MM
,
Morgan
 
PR
,
Challacombe
 
SJ
,
De Vita
 
S
, et al.  
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren’s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization
.
J Immunol
 
2008
,
180
,
5130
–
40
.

89

Tzioufas
 
AG
,
Hantoumi
 
I
,
Polihronis
 
M
,
Xanthou
 
G
,
Moutsopoulos
 
HM
.
Autoantibodies to La/SSB in patients with primary Sjogren’s syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs)
.
J Autoimmun
 
1999
,
13
,
429
–
34
.

90

de Wilde
 
PC
,
Kater
 
L
,
Bodeutsch
 
C
,
van den Hoogen
 
FH
,
van de Putte
 
LB
,
van Venrooij
 
WJ
.
Aberrant expression pattern of the SS-B/La antigen in the labial salivary glands of patients with Sjogren’s syndrome
.
Arthritis Rheum
 
1996
,
39
,
783
–
91
.

91

Yannopoulos
 
DI
,
Roncin
 
S
,
Lamour
 
A
,
Pennec
 
YL
,
Moutsopoulos
 
HM
,
Youinou
 
P
.
Conjunctival epithelial cells from patients with Sjogren’s syndrome inappropriately express major histocompatibility complex molecules, La(SSB) antigen, and heat-shock proteins
.
J Clin Immunol
 
1992
,
12
,
259
–
65
.

92

Katsiougiannis
 
S
,
Tenta
 
R
,
Skopouli
 
FN
.
Endoplasmic reticulum stress causes autophagy and apoptosis leading to cellular redistribution of the autoantigens Ro/Sjogren’s syndrome-related antigen A (SSA) and La/SSB in salivary gland epithelial cells
.
Clin Exp Immunol
 
2015
,
181
,
244
–
52
.

93

Bendaoud
 
B
,
Pennec
 
YL
,
Lelong
 
A
,
Le Noac'h
 
JF
,
Magadur
 
G
,
Jouquan
 
J
, et al.  
IgA-containing immune complexes in the circulation of patients with primary Sjogren’s syndrome
.
J Autoimmun
 
1991
,
4
,
177
–
84
.

94

Hazi-Mihailovic
 
M
,
Jankovic
 
L
,
Cakic
 
S
.
[Circulating immune complexes, immunoglobulin G, salivary proteins and salivary immunoglobulin A in patients with Sjogren’s syndrome]
.
Srp Arh Celok Lek
 
2009
,
137
,
134
–
9
.

95

Fischbach
 
M
,
Char
 
D
,
Christensen
 
M
,
Daniels
 
T
,
Whaley
 
K
,
Alspaugh
 
M
, et al.  
Immune complexes in Sjogren’s syndrome
.
Arthritis Rheum
 
1980
,
23
,
791
–
5
.

96

Yamane
 
K
,
Nakamura
 
H
,
Hamasaki
 
M
,
Minei
 
Y
,
Aibara
 
N
,
Shimizu
 
T
, et al.  
Immune complexome analysis reveals the presence of immune complexes and identifies disease-specific immune complex antigens in saliva samples from patients with Sjogren’s syndrome
.
Clin Exp Immunol
 
2021
,
204
,
212
–
20
.

97

Hillen
 
MR
,
Urso
 
K
,
Koppe
 
E
,
Lopes
 
AP
,
Blokland
 
SLM
,
Pandit
 
A
, et al.  
Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjogren’s syndrome is associated with B cell hyperactivity and type I interferon activity
.
RMD Open
 
2020
,
6
,
e001184
.

98

Ittah
 
M
,
Miceli-Richard
 
C
,
Eric Gottenberg
 
J
,
Lavie
 
F
,
Lazure
 
T
,
Ba
 
N
, et al.  
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren’s syndrome
.
Arthritis Res Ther
 
2006
,
8
,
R51
.

99

Vosters
 
JL
,
Roescher
 
N
,
Polling
 
EJ
,
Illei
 
GG
,
Tak
 
PP
.
The expression of APRIL in Sjogren’s syndrome: aberrant expression of APRIL in the salivary gland
.
Rheumatology (Oxford)
 
2012
,
51
,
1557
–
62
.

100

Vakrakou
 
AG
,
Polyzos
 
A
,
Kapsogeorgou
 
EK
,
Thanos
 
D
,
Manoussakis
 
MN
.
Impaired anti-inflammatory activity of PPARgamma in the salivary epithelia of Sjogren’s syndrome patients imposed by intrinsic NF-kappaB activation
.
J Autoimmun
 
2018
,
86
,
62
–
74
.

101

Vakrakou
 
AG
,
Polyzos
 
A
,
Kapsogeorgou
 
EK
,
Thanos
 
D
,
Manoussakis
 
MN
.
Perturbation of transcriptome in non-neoplastic salivary gland epithelial cell lines derived from patients with primary Sjogren’s syndrome
.
Data Brief
 
2018
,
17
,
194
–
9
.

102

Konsta
 
OD
,
Thabet
 
Y
,
Le Dantec
 
C
,
Brooks
 
WH
,
Tzioufas
 
AG
,
Pers
 
JO
, et al.  
The contribution of epigenetics in Sjogren’s syndrome
.
Front Genet
 
2014
,
5
,
71
.

103

Le Dantec
 
C
,
Varin
 
MM
,
Brooks
 
WH
,
Pers
 
JO
,
Youinou
 
P
,
Renaudineau
 
Y
.
Epigenetics and Sjogren’s syndrome
.
Curr Pharm Biotechnol
 
2012
,
13
,
2046
–
53
.

104

Wang
 
Y
,
Riaz
 
F
,
Wang
 
W
,
Pu
 
J
,
Liang
 
Y
,
Wu
 
Z
, et al.  
Functional significance of DNA methylation: epigenetic insights into Sjogren’s syndrome
.
Front Immunol
 
2024
,
15
,
1289492
.

105

Chi
 
C
,
Solomon
 
O
,
Shiboski
 
C
,
Taylor
 
KE
,
Quach
 
H
,
Quach
 
D
, et al.  
Identification of Sjogren’s syndrome patient subgroups by clustering of labial salivary gland DNA methylation profiles
.
PLoS One
 
2023
,
18
,
e0281891
.

106

Sepulveda
 
D
,
Barrera
 
MJ
,
Castro
 
I
,
Aguilera
 
S
,
Carvajal
 
P
,
Lagos
 
C
, et al.  
Impaired IRE1alpha/XBP-1 pathway associated to DNA methylation might contribute to salivary gland dysfunction in Sjogren’s syndrome patients
.
Rheumatology (Oxford)
 
2018
,
57
,
1021
–
32
.

107

Konsta
 
OD
,
Le Dantec
 
C
,
Charras
 
A
,
Cornec
 
D
,
Kapsogeorgou
 
EK
,
Tzioufas
 
AG
, et al.  
Defective DNA methylation in salivary gland epithelial acini from patients with Sjogren’s syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration
.
J Autoimmun
 
2016
,
68
,
30
–
8
.

108

Hyphantis
 
T
,
Mantis
 
D
,
Voulgari
 
PV
,
Tsifetaki
 
N
,
Drosos
 
AA
.
The psychological defensive profile of primary Sjogren’s syndrome patients and its relationship to health-related quality of life
.
Clin Exp Rheumatol
 
2011
,
29
,
485
–
93
.

109

Johnson
 
EO
,
Skopouli
 
FN
,
Moutsopoulos
 
HM
.
Neuroendocrine manifestations in Sjogren’s syndrome
.
Rheum Dis Clin North Am
 
2000
,
26
,
927
–
49
.

110

Johnson
 
EO
,
Vlachoyiannopoulos
 
PG
,
Skopouli
 
FN
,
Tzioufas
 
AG
,
Moutsopoulos
 
HM
.
Hypofunction of the stress axis in Sjogren’s syndrome
.
J Rheumatol
 
1998
,
25
,
1508
–
14
.

111

Karaiskos
 
D
,
Mavragani
 
CP
,
Makaroni
 
S
,
Zinzaras
 
E
,
Voulgarelis
 
M
,
Rabavilas
 
A
, et al.  
Stress, coping strategies and social support in patients with primary Sjogren’s syndrome prior to disease onset: a retrospective case-control study
.
Ann Rheum Dis
 
2009
,
68
,
40
–
6
.

112

Hsu
 
TW
,
Bai
 
YM
,
Tsai
 
SJ
,
Chen
 
TJ
,
Chen
 
MH
,
Liang
 
CS
.
Risk of autoimmune diseases after post-traumatic stress disorder: a nationwide cohort study
.
Eur Arch Psychiatry Clin Neurosci
 
2024
,
274
,
487
–
95
.

113

Moustaka
 
K
,
Stergiopoulos
 
A
,
Tenta
 
R
,
Havaki
 
S
,
Katsiougiannis
 
S
,
Skopouli
 
FN
.
Beta-adrenergic stimulation promotes an endoplasmic reticulum stress-dependent inflammatory program in salivary gland epithelial cells
.
Clin Exp Immunol
 
2024
,
218
,
65
–
74
.

114

Apostolou
 
E
,
Moustardas
 
P
,
Iwawaki
 
T
,
Tzioufas
 
AG
,
Spyrou
 
G
.
Ablation of the chaperone protein ERdj5 results in a Sjogren’s syndrome-like phenotype in mice, consistent with an upregulated unfolded protein response in human patients
.
Front Immunol
 
2019
,
10
,
506
.

115

Hosoda
 
A
,
Tokuda
 
M
,
Akai
 
R
,
Kohno
 
K
,
Iwawaki
 
T
.
Positive contribution of ERdj5/JPDI to endoplasmic reticulum protein quality control in the salivary gland
.
Biochem J
 
2009
,
425
,
117
–
25
.

Author notes

Conflicts of interest: The authors declare no conflicts of interest.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period